STTK
Shattuck Labs, Inc.
NASDAQ · Healthcare · Biotechnology · US
$6.79
−2.44%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.0M | 1.0M | 5.7M | 1.7M | 652.0K |
| Cost of Revenue | 8.5M | 3.0M | 4.9M | 4.0M | 82.2M |
| Gross Profit | (7.5M) | (2.0M) | 827.0K | (2.4M) | (81.5M) |
| Operating Expenses | |||||
| R&D Expense | 39.3M | 35.3M | 67.2M | 74.3M | 82.9M |
| SG&A Expense | 17.5M | 17.2M | 19.1M | 19.3M | 19.7M |
| General & Admin Expense | 17.5M | 17.2M | 19.1M | 19.3M | 19.7M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (8.5M) | (3.0M) | (4.9M) | (4.0M) | (80.8M) |
| Total Operating Expenses | 48.3M | 49.6M | 81.4M | 89.6M | 21.8M |
| Cost and Expenses | 56.8M | 52.5M | 86.3M | 93.6M | 104.0M |
| Operating Income (EBIT) | (55.8M) | (51.5M) | (80.6M) | (92.0M) | (103.3M) |
| Non-Operating | |||||
| Interest Income | 1.8M | 2.7M | 5.2M | 4.7M | 1.6M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 1.8M | 2.7M | 5.2M | 4.7M | 1.6M |
| Other Non-Op Income/Expense | 3.2M | 2.7M | 5.2M | 4.7M | 1.4M |
| Non-Operating Income (excl Interest) | (3.2M) | (2.7M) | (5.2M) | (4.7M) | (1.4M) |
| EBT (Pre-Tax Income) | (52.6M) | (48.8M) | (75.4M) | (87.3M) | (101.9M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (52.6M) | (48.8M) | (75.4M) | (87.3M) | (101.9M) |
| Earnings from Cont. Ops | (52.6M) | (48.8M) | (75.4M) | (87.3M) | (101.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (52.6M) | (48.8M) | (75.4M) | (87.3M) | (101.9M) |
| Per Share | |||||
| Basic EPS | ($0.51) | ($0.70) | ($1.49) | ($2.05) | ($2.41) |
| Diluted EPS | ($0.51) | ($0.70) | ($1.49) | ($2.05) | ($2.41) |
| Revenue Per Share | $0.01 | $0.01 | $0.11 | $0.04 | $0.02 |
| Shares | |||||
| Basic Shares Outstanding | 129.8M | 69.6M | 50.8M | 42.6M | 42.4M |
| Diluted Shares Outstanding | 129.8M | 69.6M | 50.8M | 42.6M | 42.4M |
| Profitability Metrics | |||||
| EBITDA | (48.5M) | (45.1M) | (71.6M) | (83.3M) | (98.9M) |
| D&A | 4.1M | 3.7M | 3.8M | 4.0M | 3.1M |
| EBIT | (52.6M) | (48.8M) | (75.4M) | (87.3M) | (101.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026